Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.42 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | RORB | Q92753 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305677 | 0.83 | VCAM1 (0.54) | LMNAKMT2AMEN1VCAM1MAPT | |
| SCHEMBL306592 | 0.77 | RECQL (0.56) | LMNAKMT2AMAPK13MAPK12MAPK11 | |
| SCHEMBL305749 | 0.76 | MAPT (0.51) | LMNAKMT2AMEN1MAPTNPC1 | |
| SCHEMBL307562 | 0.76 | CASP6 (0.40) | LMNAKMT2AMEN1VCAM1MAPT | |
| SCHEMBL10222533 | 0.76 | POLB (0.39) | LMNAKMT2AMEN1VCAM1KCNMA1 | |
| SCHEMBL11709505 | 0.75 | LMNA (0.50) | LMNAKMT2AMEN1MAPK13MAPK12 | |
| SCHEMBL8578210 | 0.75 | LMNA (0.62) | LMNAKMT2AMEN1MAPK13MAPK12 | |
| SCHEMBL13240120 | 0.74 | RECQL (0.65) | LMNAKMT2AMEN1MAPK13MAPK12 | |
| SCHEMBL15268202 | 0.74 | RECQL (0.42) | LMNAKMT2AMAPK13MAPK12MAPK11 | |
| SCHEMBL18714222 | 0.73 | POLB (0.51) | LMNAKMT2AMEN1VCAM1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | LMNA 4645/4885KMT2A 2475/4885MEN1 4873/4885 |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | LMNA 4645/4885KMT2A 2475/4885MEN1 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.